TDMS Study 05165-02 Pathology Tables
NTP Experiment-Test: 05165-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 4,4 THIOBIS-(6-T-BUTYL-M-CRESOL) Date: 11/09/95
Route: DOSED FEED Time: 20:28:46
Facility: Battelle Columbus Laboratory
Chemical CAS #: 96-69-5
Lock Date: 01/10/92
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05165-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 4,4 THIOBIS-(6-T-BUTYL-M-CRESOL) Date: 11/09/95
Route: DOSED FEED Time: 20:28:46
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM 250 PPM 500 PPM 1000 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 60 60 60 60
Scheduled Sacrifice 9 9 10 10
Early Deaths
Natural Death 7 9 11 11
Moribund Sacrifice 4 3 3 4
Survivors
Natural Death 1
Terminal Sacrifice 39 38 36 35
Missing 1
Animals Examined Microscopically 60 59 60 60
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Small, Jejunum (59) (59) (60) (60)
Necrosis, Focal 1 (2%)
Liver (60) (59) (60) (60)
Angiectasis 2 (3%) 1 (2%)
Basophilic Focus 2 (3%) 4 (7%) 3 (5%)
Clear Cell Focus 2 (3%) 3 (5%)
Eosinophilic Focus 10 (17%) 8 (14%) 10 (17%) 7 (12%)
Hematopoietic Cell Proliferation 2 (3%) 4 (7%) 1 (2%)
Inflammation, Chronic Active 1 (2%)
Necrosis 1 (2%) 1 (2%)
Vacuolization Cytoplasmic 1 (2%)
Bile Duct, Cyst 2 (3%)
Bile Duct, Dilatation 1 (2%)
Hepatocyte, Fatty Change 7 (12%) 6 (10%) 5 (8%) 6 (10%)
Hepatocyte, Hypertrophy 2 (3%)
Periportal, Inflammation, Chronic Active 1 (2%)
Serosa, Inflammation, Chronic 1 (2%)
Mesentery (5) (6) (4) (1)
Fat, Inflammation, Chronic Active 4 (80%) 3 (50%) 1 (25%) 1 (100%)
Pancreas (59) (59) (59) (60)
Inflammation, Chronic Active 1 (2%)
Acinus, Atrophy 1 (2%) 3 (5%) 2 (3%)
Duct, Cyst 1 (2%)
Pharynx (1)
Submucosa, Palate, Infiltration Cellular,
Mast Cell 1 (100%)
Stomach, Forestomach (59) (59) (60) (60)
Acanthosis, Multifocal 1 (2%)
Ulcer 1 (2%)
Stomach, Glandular (59) (59) (60) (60)
a Number of animals examined microscopically at site and number of animals with lesion
Page 2
NTP Experiment-Test: 05165-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 4,4 THIOBIS-(6-T-BUTYL-M-CRESOL) Date: 11/09/95
Route: DOSED FEED Time: 20:28:46
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM 250 PPM 500 PPM 1000 PPM
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Necrosis 1 (2%) 1 (2%)
Mucosa, Hyperplasia 1 (2%)
Submucosa, Inflammation, Chronic Active 1 (2%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (60) (59) (60) (60)
Degeneration, Chronic 2 (3%) 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (60) (59) (60) (60)
Cyst 2 (3%) 1 (2%) 1 (2%)
Hematopoietic Cell Proliferation 1 (2%)
Hyperplasia 2 (3%) 1 (2%) 1 (2%)
Hypertrophy 3 (5%) 6 (10%) 5 (8%) 3 (5%)
Capsule, Accessory Adrenal Cortical Nodule 1 (2%) 2 (3%) 1 (2%)
Adrenal Medulla (58) (59) (60) (60)
Hyperplasia 2 (3%) 1 (2%) 3 (5%)
Parathyroid Gland (52) (54) (57) (57)
Cyst 1 (2%)
Pituitary Gland (57) (58) (59) (58)
Pars Distalis, Angiectasis 2 (3%)
Pars Distalis, Cyst 4 (7%) 3 (5%)
Pars Distalis, Hyperplasia 9 (16%) 14 (24%) 13 (22%) 11 (19%)
Pars Distalis, Hypertrophy 1 (2%)
Pars Intermedia, Cyst 1 (2%)
Pars Intermedia, Hyperplasia 1 (2%)
Thyroid Gland (60) (59) (59) (60)
Cyst 1 (2%)
Inflammation, Chronic Active 1 (2%)
Ultimobranchial Cyst 1 (2%)
Follicle, Cyst 2 (3%) 1 (2%)
Follicle, Cyst, Multiple 1 (2%)
Follicular Cell, Hyperplasia 4 (7%) 2 (3%) 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 3
NTP Experiment-Test: 05165-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 4,4 THIOBIS-(6-T-BUTYL-M-CRESOL) Date: 11/09/95
Route: DOSED FEED Time: 20:28:46
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM 250 PPM 500 PPM 1000 PPM
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Clitoral Gland (51) (45) (48) (44)
Duct, Dilatation 1 (2%) 1 (2%)
Ovary (59) (59) (59) (60)
Angiectasis 1 (2%)
Inflammation, Granulomatous 1 (2%) 1 (2%)
Mineralization 2 (3%) 1 (2%)
Thrombosis 1 (2%)
Bilateral, Inflammation, Granulomatous 2 (3%) 1 (2%)
Bilateral, Periovarian Tissue, Cyst 1 (2%)
Bilateral, Follicle, Cyst 3 (5%) 2 (3%) 4 (7%)
Follicle, Cyst 26 (44%) 22 (37%) 23 (39%) 21 (35%)
Periovarian Tissue, Cyst 1 (2%) 3 (5%) 8 (13%)
Periovarian Tissue, Inflammation,
Granulomatous 1 (2%)
Rete Ovarii, Hyperplasia 2 (3%) 1 (2%)
Uterus (60) (59) (60) (60)
Endometrium, Hyperplasia, Cystic, Glandular 57 (95%) 57 (97%) 52 (87%) 57 (95%)
Endometrium, Vein, Thrombosis 2 (3%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (60) (59) (60) (60)
Myelofibrosis 21 (35%) 18 (31%) 23 (38%) 34 (57%)
Femoral, Myelofibrosis 1 (2%) 1 (2%)
Lymph Node (9) (7) (4) (7)
Inguinal, Inflammation, Chronic Active 1 (14%)
Mediastinal, Hyperplasia, Lymphoid 1 (14%)
Mediastinal, Infiltration Cellular,
Histiocyte 1 (11%)
Mediastinal, Inflammation, Acute 1 (14%)
Lymph Node, Mandibular (59) (59) (57) (60)
Congestion 2 (3%)
Hematopoietic Cell Proliferation 1 (2%)
Hyperplasia, Lymphoid 1 (2%)
Infiltration Cellular, Histiocyte 6 (10%)
Inflammation, Chronic Active 1 (2%)
Lymphocyte, Necrosis 1 (2%)
Lymph Node, Mesenteric (52) (51) (51) (52)
Cyst 1 (2%)
Hematopoietic Cell Proliferation 1 (2%)
Hyperplasia, Histiocytic, Macrophage 40 (77%) 33 (65%) 31 (61%) 42 (81%)
Infiltration Cellular, Histiocyte 5 (10%) 3 (6%) 9 (18%) 9 (17%)
Inflammation, Chronic Active 1 (2%) 1 (2%)
Lymphatic, Cyst 1 (2%)
Lymphocyte, Necrosis 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 4
NTP Experiment-Test: 05165-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 4,4 THIOBIS-(6-T-BUTYL-M-CRESOL) Date: 11/09/95
Route: DOSED FEED Time: 20:28:46
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM 250 PPM 500 PPM 1000 PPM
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - CONT
Spleen (60) (59) (60) (59)
Depletion Lymphoid 2 (3%)
Fibrosis 1 (2%)
Hematopoietic Cell Proliferation 8 (13%) 12 (20%) 7 (12%) 4 (7%)
Inflammation, Chronic 1 (2%)
Lymphocyte, Necrosis 1 (2%)
Thymus (55) (52) (54) (58)
Concretion 1 (2%)
Depletion Lymphoid 6 (11%) 2 (4%) 8 (15%) 4 (7%)
Necrosis 1 (2%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (59) (59) (58) (59)
Hyperplasia, Cystic 2 (3%) 2 (3%) 2 (3%)
Skin (60) (59) (60) (60)
Inguinal, Ulcer 1 (2%)
Subcutaneous Tissue, Hemorrhage 1 (2%)
Subcutaneous Tissue, Inflammation, Acute 1 (2%)
Tail, Ulcer 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Skeletal Muscle (60) (59) (60) (60)
Hemorrhage 1 (2%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (60) (59) (60) (60)
Compression 1 (2%) 3 (5%) 3 (5%)
Necrosis 1 (2%)
Neuron, Degeneration 1 (2%)
Peripheral Nerve (2) (1) (1) (4)
Sciatic, Axon, Degeneration 2 (100%) 1 (100%) 1 (100%) 4 (100%)
Spinal Cord (2) (1) (1) (4)
Axon, Degeneration 1 (50%) 2 (50%)
Lumbar, Axon, Nerve, Degeneration 1 (50%) 1 (100%) 4 (100%)
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 5
NTP Experiment-Test: 05165-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 4,4 THIOBIS-(6-T-BUTYL-M-CRESOL) Date: 11/09/95
Route: DOSED FEED Time: 20:28:46
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE 0 PPM 250 PPM 500 PPM 1000 PPM
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (60) (59) (60) (60)
Congestion 1 (2%)
Hemorrhage, Focal 1 (2%)
Inflammation, Acute 1 (2%)
Alveolar Epithelium, Hyperplasia 2 (3%)
Alveolar Epithelium, Hyperplasia, Macrophage 1 (2%)
Mediastinum, Inflammation, Chronic Active 1 (2%) 1 (2%)
Perivascular, Infiltration Cellular,
Lymphocyte 4 (7%) 5 (8%) 3 (5%) 7 (12%)
Perivascular, Inflammation, Chronic Active 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (1) (1) (1)
Atrophy 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (60) (59) (60) (60)
Amyloid Deposition 1 (2%) 1 (2%)
Metaplasia, Focal, Osseous 1 (2%)
Nephropathy, Chronic 22 (37%) 27 (46%) 16 (27%) 18 (30%)
Cortex, Cyst 1 (2%)
Cortex, Infarct 1 (2%) 2 (3%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 6
NTP Experiment-Test: 05165-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 4,4 THIOBIS-(6-T-BUTYL-M-CRESOL) Date: 11/09/95
Route: DOSED FEED Time: 20:28:46
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 PPM 250 PPM 500 PPM 1000 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 60 60 60 60
Scheduled Sacrifice 10 10 10 10
Early Deaths
Natural Death 6 6 1 4
Moribund Sacrifice 2 2 1
Survivors
Natural Death 1 1
Terminal Sacrifice 41 41 49 45
Animals Examined Microscopically 60 60 60 60
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Intestine Small, Jejunum (60) (60) (60) (60)
Mucosa, Hyperplasia 1 (2%)
Peyer's Patch, Hyperplasia, Lymphoid 1 (2%)
Peyer's Patch, Ulcer, Chronic Active 1 (2%)
Intestine Small, Ileum (60) (60) (59) (59)
Peyer's Patch, Inflammation, Acute 1 (2%)
Liver (60) (60) (60) (60)
Basophilic Focus 1 (2%)
Clear Cell Focus 6 (10%) 2 (3%) 2 (3%)
Clear Cell Focus, Multiple 3 (5%)
Congestion 1 (2%)
Eosinophilic Focus 2 (3%) 3 (5%) 3 (5%)
Hematopoietic Cell Proliferation 1 (2%)
Infarct 1 (2%)
Necrosis 2 (3%) 1 (2%) 1 (2%) 1 (2%)
Thrombosis 1 (2%) 1 (2%)
Vacuolization Cytoplasmic 6 (10%) 2 (3%) 3 (5%) 1 (2%)
Bile Duct, Cyst 1 (2%)
Bile Duct, Hyperplasia 1 (2%)
Hepatocyte, Fatty Change 19 (32%) 17 (28%) 5 (8%) 6 (10%)
Serosa, Fibrosis 1 (2%)
Vein, Dilatation 1 (2%)
Mesentery (1) (2) (1)
Fat, Inflammation, Chronic Active 1 (100%) 2 (100%)
Pancreas (60) (60) (60) (60)
Acinus, Atrophy 1 (2%) 3 (5%) 1 (2%) 2 (3%)
Acinus, Karyomegaly 1 (2%)
Duct, Cyst 1 (2%) 1 (2%)
Salivary Glands (60) (60) (60) (60)
Acinus, Atrophy 1 (2%)
Stomach, Forestomach (60) (60) (60) (60)
a Number of animals examined microscopically at site and number of animals with lesion
Page 7
NTP Experiment-Test: 05165-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 4,4 THIOBIS-(6-T-BUTYL-M-CRESOL) Date: 11/09/95
Route: DOSED FEED Time: 20:28:46
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 PPM 250 PPM 500 PPM 1000 PPM
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Acanthosis 1 (2%) 1 (2%)
Acanthosis, Multifocal 1 (2%)
Stomach, Glandular (60) (60) (60) (60)
Submucosa, Developmental Malformation 2 (3%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (60) (60) (60) (60)
Aortic Valve, Thrombosis 1 (2%)
Atrium, Thrombosis 1 (2%)
Ventricle Right, Thrombosis 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (60) (60) (60) (60)
Accessory Adrenal Cortical Nodule 1 (2%)
Ectopic Tissue 1 (2%)
Hyperplasia 1 (2%) 4 (7%)
Hypertrophy 30 (50%) 30 (50%) 26 (43%) 25 (42%)
Vacuolization Cytoplasmic 1 (2%)
Capsule, Accessory Adrenal Cortical Nodule 1 (2%) 1 (2%)
Adrenal Medulla (60) (60) (60) (60)
Hyperplasia 1 (2%) 1 (2%)
Islets, Pancreatic (60) (60) (60) (60)
Hyperplasia 3 (5%) 2 (3%) 1 (2%)
Parathyroid Gland (59) (58) (56) (57)
Cyst 2 (3%) 1 (2%)
Pituitary Gland (55) (56) (58) (57)
Craniopharyngeal Duct, Cyst 1 (2%)
Pars Distalis, Cyst 1 (2%) 3 (5%) 2 (4%)
Pars Distalis, Hyperplasia 1 (2%)
Thyroid Gland (60) (60) (60) (60)
Follicle, Cyst 3 (5%) 1 (2%) 1 (2%)
Follicular Cell, Hyperplasia 1 (2%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 8
NTP Experiment-Test: 05165-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 4,4 THIOBIS-(6-T-BUTYL-M-CRESOL) Date: 11/09/95
Route: DOSED FEED Time: 20:28:46
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 PPM 250 PPM 500 PPM 1000 PPM
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (60) (60) (60) (60)
Developmental Malformation 1 (2%)
Inflammation, Chronic Active 1 (2%) 2 (3%) 2 (3%)
Preputial Gland (55) (49) (54) (51)
Inflammation, Chronic Active 3 (5%) 2 (4%) 4 (7%) 2 (4%)
Duct, Dilatation 27 (49%) 14 (29%) 16 (30%) 19 (37%)
Seminal Vesicle (50) (50) (50) (50)
Inflammation, Chronic Active 1 (2%)
Testes (60) (60) (60) (60)
Developmental Malformation 1 (2%)
Mineralization 1 (2%)
Spermatocele 1 (2%)
Interstitial Cell, Hyperplasia 2 (3%)
Seminiferous Tubule, Atrophy 2 (3%) 1 (2%) 1 (2%) 2 (3%)
Seminiferous Tubule, Mineralization 2 (3%)
Tunic, Inflammation, Chronic 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Lymph Node, Mandibular (59) (57) (57) (58)
Depletion Lymphoid 1 (2%)
Infiltration Cellular, Plasma Cell 1 (2%)
Infiltration Cellular, Histiocyte 1 (2%) 1 (2%) 1 (2%) 1 (2%)
Lymph Node, Mesenteric (58) (55) (58) (55)
Congestion 1 (2%) 1 (2%)
Depletion Lymphoid 2 (3%) 3 (5%)
Hematopoietic Cell Proliferation 1 (2%)
Hyperplasia, Histiocytic, Macrophage 48 (83%) 37 (67%) 44 (76%) 45 (82%)
Infiltration Cellular, Histiocyte 3 (5%) 6 (11%) 9 (16%) 8 (15%)
Spleen (60) (60) (60) (60)
Angiectasis 1 (2%)
Depletion Lymphoid 1 (2%) 1 (2%) 1 (2%)
Hematopoietic Cell Proliferation 5 (8%) 3 (5%) 4 (7%) 5 (8%)
Hemorrhage 1 (2%)
Thymus (56) (56) (56) (54)
Angiectasis 1 (2%)
Cyst 1 (2%) 1 (2%)
Depletion Lymphoid 12 (21%) 6 (11%) 2 (4%) 3 (6%)
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 9
NTP Experiment-Test: 05165-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 4,4 THIOBIS-(6-T-BUTYL-M-CRESOL) Date: 11/09/95
Route: DOSED FEED Time: 20:28:46
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 PPM 250 PPM 500 PPM 1000 PPM
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (60) (60) (60) (60)
Subcutaneous Tissue, Inflammation, Chronic
Active 1 (2%) 1 (2%)
Thoracic, Ulcer 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (60) (60) (60) (58)
Maxilla, Inflammation, Chronic Active,
Necrotizing 1 (2%)
Skeletal Muscle (60) (60) (60) (60)
Diaphragm, Degeneration, Chronic 1 (2%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Peripheral Nerve (1) (1)
Sciatic, Axon, Degeneration 1 (100%)
Spinal Cord (1)
Axon, Degeneration 1 (100%)
Lumbar, Axon, Nerve, Degeneration 1 (100%)
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Lung (60) (60) (60) (60)
Inflammation, Chronic Active 1 (2%)
Alveolar Epithelium, Hyperplasia 2 (3%) 4 (7%) 2 (3%) 3 (5%)
Alveolar Epithelium, Hyperplasia, Macrophage 1 (2%)
Alveolus, Hyperplasia, Macrophage 1 (2%)
Perivascular, Infiltration Cellular,
Lymphocyte 4 (7%) 5 (8%) 7 (12%) 10 (17%)
Subpleura, Infiltration Cellular, Lymphocyte 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (2) (2) (1)
Atrophy 1 (100%)
Cornea, Hyperplasia, Squamous 1 (50%) 2 (100%)
Cornea, Inflammation, Chronic Active 1 (50%) 2 (100%)
Harderian Gland (3) (4) (3)
Hyperplasia 1 (25%)
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 10
NTP Experiment-Test: 05165-02 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC 4,4 THIOBIS-(6-T-BUTYL-M-CRESOL) Date: 11/09/95
Route: DOSED FEED Time: 20:28:46
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE 0 PPM 250 PPM 500 PPM 1000 PPM
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (60) (60) (60) (60)
Hydronephrosis 1 (2%) 1 (2%)
Infiltration Cellular, Mast Cell 1 (2%)
Nephropathy, Chronic 56 (93%) 55 (92%) 60 (100%) 56 (93%)
Cortex, Cyst 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 11
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------